+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anthrax - Pipeline Review, H1 2020

  • ID: 4986863
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 110 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Altimmune Inc
  • Biologics Resources LLC
  • Dynavax Technologies Corp
  • GC Pharma
  • iBio Inc
  • Opal Biosciences Ltd
  • MORE
Anthrax - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H1 2020, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Altimmune Inc
  • Biologics Resources LLC
  • Dynavax Technologies Corp
  • GC Pharma
  • iBio Inc
  • Opal Biosciences Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Anthrax - Overview
  • Anthrax - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Anthrax - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Anthrax - Companies Involved in Therapeutics Development
  • Altimmune Inc
  • Aphios Corp
  • Aradigm Corp
  • Biologics Resources LLC
  • BlueWillow Biologics Inc
  • Companhia Industrial Produtora de Antibioticos SA
  • Crestone Inc
  • Dynavax Technologies Corp
  • Elusys Therapeutics Inc
  • Emergent BioSolutions Inc
  • GC Pharma
  • Greffex Inc
  • Hawaii Biotech Inc
  • iBio Inc
  • Innovative Biologics Inc
  • Integrated BioTherapeutics Inc
  • iNtRON Biotechnology Inc
  • Opal Biosciences Ltd
  • Protein Potential LLC
  • ProThera Biologics Inc
  • Soligenix Inc
  • Tetraphase Pharmaceuticals Inc
  • Vast Therapeutics Inc
  • Venomyx Inc
  • VLP Biotech Inc
  • Anthrax - Drug Profiles
  • Anthrax - Dormant Projects
  • Anthrax - Discontinued Products
  • Anthrax - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Anthrax, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Anthrax - Pipeline by Altimmune Inc, H1 2020
  • Anthrax - Pipeline by Aphios Corp, H1 2020
  • Anthrax - Pipeline by Aradigm Corp, H1 2020
  • Anthrax - Pipeline by Biologics Resources LLC, H1 2020
  • Anthrax - Pipeline by BlueWillow Biologics Inc, H1 2020
  • Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H1 2020
  • Anthrax - Pipeline by Crestone Inc, H1 2020
  • Anthrax - Pipeline by Dynavax Technologies Corp, H1 2020
  • Anthrax - Pipeline by Elusys Therapeutics Inc, H1 2020
  • Anthrax - Pipeline by Emergent BioSolutions Inc, H1 2020
  • Anthrax - Pipeline by GC Pharma, H1 2020
  • Anthrax - Pipeline by Greffex Inc, H1 2020
  • Anthrax - Pipeline by Hawaii Biotech Inc, H1 2020
  • Anthrax - Pipeline by iBio Inc, H1 2020
  • Anthrax - Pipeline by Innovative Biologics Inc, H1 2020
  • Anthrax - Pipeline by Integrated BioTherapeutics Inc, H1 2020
  • Anthrax - Pipeline by iNtRON Biotechnology Inc, H1 2020
  • Anthrax - Pipeline by Opal Biosciences Ltd, H1 2020
  • Anthrax - Pipeline by Protein Potential LLC, H1 2020
  • Anthrax - Pipeline by ProThera Biologics Inc, H1 2020
  • Anthrax - Pipeline by Soligenix Inc, H1 2020
  • Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2020
  • Anthrax - Pipeline by Vast Therapeutics Inc, H1 2020
  • Anthrax - Pipeline by Venomyx Inc, H1 2020
  • Anthrax - Pipeline by VLP Biotech Inc, H1 2020
  • Anthrax - Dormant Projects, H1 2020
  • Anthrax - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Anthrax, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Altimmune Inc
  • Aphios Corp
  • Aradigm Corp
  • Biologics Resources LLC
  • BlueWillow Biologics Inc
  • Companhia Industrial Produtora de Antibioticos SA
  • Crestone Inc
  • Dynavax Technologies Corp
  • Elusys Therapeutics Inc
  • Emergent BioSolutions Inc
  • GC Pharma
  • Greffex Inc
  • Hawaii Biotech Inc
  • iBio Inc
  • Innovative Biologics Inc
  • Integrated BioTherapeutics Inc
  • iNtRON Biotechnology Inc
  • Opal Biosciences Ltd
  • Protein Potential LLC
  • ProThera Biologics Inc
  • Soligenix Inc
  • Tetraphase Pharmaceuticals Inc
  • Vast Therapeutics Inc
  • Venomyx Inc
  • VLP Biotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll